

Financial Tear Sheet

Dimension Therapeutics, Inc. is a rare disease company focused on discovering and developing new therapeutic products for people living with devastating rare diseases associated with the liver and based on the most advanced adeno-associated virus (AAV) delivery technology. The company is advancing multiple programs toward clinical development, including: programs addressing unmet needs for patients suffering from GSDIa, phenylketonuria (PKU), Wilson disease, and citrullinemia; a collaboration with Bayer HealthCare in hemophilia A, and a wholly owned program in OTC deficiency, which is in a Phase 1/2 clinical trial. Dimension has preferred access to multiple AAV vectors from REGENXBIO. The Dimension team and senior advisors include biotech industry veterans and renowned thought leaders in gene therapy and rare diseases.

PRIMARY IR CONTACT

Jean Franchi
Chief Financial Officer
Phone: 617-714-0709
E-mail:
ir@dimensiontx.com


STOCK INFORMATION

DMTX (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$5.95
Change (%)	0.00 (0.00%)
Volume	0
52 Week Low	\$1.05
Market Cap	\$149,994,460
Rolling EPS	-2.23
PE Ratio	0

Shares Outstanding 25,209,153

Data as of 11/06/17 4:00 p.m. ET



Data provided by Nasdaq. Minimum 15 minutes delayed.

RECENT PRESS RELEASES & EVENTS

October 26, 2017 - 11:03 a.m.

Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension

There are currently no events scheduled.

October 02, 2017 - 8:00 a.m.

Dimension Board Determines that Ultragenyx's Unsolicited Proposal to Acquire Dimension for \$6.00 Per Share Constitutes a "Superior Proposal"

September 19, 2017 - 8:01 a.m.

Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a "Superior Proposal"

SEC FILINGS

Filing Date	Form
11/17/17	15-12B
11/13/17	EFFECT
11/09/17	4
11/07/17	4